UNSPSC 51141524: Phenacemide

This classification denotes an anticonvulsant agent with the molecular formula C9H10N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PAI7J52V09, chemically known as urea, (phenylacetyl)- but generally known as phenacemide, which bears US NIH Compound Identifier 4753. European Medicines Agency schedules Phenacemide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09744MIG. The term PHENACEMIDE is an International Non-Proprietary Name.

UNSPSC 51141524 Phenacemide, a Commodity code, shows limited recent activity that does not align with its nominal pharmaceutical scope. The three recent state and local opportunities posted under this code involve naloxone and drug-deactivation systems, therapeutic pharmacy initiatives, and generic multi-source pharmaceuticals and over-the-counter products—none of which are phenacemide-specific procurement. The mismatch between the code's designation and the actual work being solicited suggests either a tagging error in the source records or that phenacemide procurement is not currently active in state and local markets under this classification.

The opportunities that do appear under this code originate from diverse issuing bodies: Seminole County, Florida (health services procurement); the Texas Health and Human Services Commission (state-level pharmacy benefit administration); and the Minnesota Multistate Cooperative Purchasing Alliance (cooperative purchasing on behalf of multiple state and local participants including Oregon). Geographic activity spans Florida, Texas, and the upper Midwest, with the MMCAP cooperative reaching multiple jurisdictions. Seminole County posted an IFB for 1,900 units of naloxone and 800 safe drug-deactivation systems annually with quarterly deliveries, due July 26, 2023; Texas HHS posted an RFI for direct-to-manufacturer prescription program capabilities on April 3, 2026; and Minnesota MMCAP issued an RFP for generic pharmaceuticals and OTC products with proposals due March 26, 2026, and contract effectiveness July 1, 2026. Given the code's apparent misalignment with recent solicitations, phenacemide-specific procurement opportunities do not currently show measurable activity in state and local markets.